



## Viral Epidemiology Snapshot: June 12-18, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV					Other Respiratory Viruses			
<u>Virus</u>		#Tested	#Positive	% Positive	<u>Virus</u>	#Tested	#Positive	% Positive
Flu A		279	6	2.2%	Adenovirus	216	12	5.6%
Flu B		279	0	0.0%	Coronavirus 229E	216	0	0.0%
RSV		218	12	5.5%	Coronavirus HKU1	216	0	0.0%
CoV-2 PUI		673	64	9.5%	Coronavirus NL63	216	4	1.9%
CoV-2 Surv	eillance	450	8	1.8%	Coronavirus OC43	216	2	0.9%
Flo. A Co.		l A Cb4	- t		Metapneumovirus	216	10	4.6%
	Flu A Subtyp 2009 H1N1		<b>ping</b> 0		Rhinovirus/Enterovirus	216	65	30.1%
	Seasonal H1		0		Parainfluenza 1	216	1	0.5%
	Seasonal H3		5		Parainfluenza 2	216	0	0.0%
	No Subtype		1		Parainfluenza 3	216	31	14.4%
	Pending subtype		0		Parainfluenza 4	216	1	0.5%





This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of Feb. '22) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of Oct. '21, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.